SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Keeta is a high-performance layer-1 blockchain designed to unify transactions across different blockchains and fiat payment systems, eliminating the need for costly intermediaries, reducing fees, and enabling near-instant settlements. With 400-millisecond transaction finality and the ability to process 10 million transactions per second, Keeta sets a new industry benchmark for speed and scalability.  Founded in 2022 and backed by Eric Schmidt, the former CEO of Google, Keeta has been engineered to meet the stringent regulatory and operational requirements of financial institutions. Its advanced on-chain compliance protocols, including KYC and AML, ensure security and regulatory adherence. Keeta’s architecture natively supports asset tokenization and digital identity, making it an ideal platform for stablecoins and real-world asset transfers.  By facilitating cross-chain transactions and interoperability with existing payment systems, Keeta bridges the gap between cryptocurrencies and fiat, enabling a secure, efficient, and compliant global financial ecosystem.

Keeta

KTA CRYPTO is drawing significant attention as a Layer 1 network building high-speed, compliance-first financial infrastructure, with a recent integration of a fiat anchor from a Stripe company enabling seamless transfers. The community is actively discussing its potential as an undervalued "asymmetric bet" set to become a foundational layer for global financial plumbing. This positioning, coupled with its proven throughput and regulatory readiness, makes it a compelling opportunity amidst the evolving crypto landscape.

Omeros Corp. operates as a biopharmaceutical company. The firm engages in the discovery, development, and commercializing of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Omeros Corporation

Omeros Corp

Omeros Corp is trending after receiving FDA approval for YARTEMLEA, the first and only therapy for transplant-associated thrombotic microangiopathy in adults and children, with commercial launch set for January. The community is buzzing with optimism, anticipating a massive short squeeze and significant undervaluation given the drug's market potential and the company's strategic partnership with Novo Nordisk. Discussion centers on the long-term holding prospects and potential for a buyout, despite some debate on near-term volatility.

Citigroup, Inc. is a holding company, which engages in the provision of financial products and services. It operates through the following segments: Services, Markets, Banking, Wealth, U.S. Personal Banking (USPB), and All Other. The Services segment includes Treasury and Trade Solutions (TTS) which provides an integrated suite of tailored cash management, trade, and working capital solutions to multinational corporations, financial institutions and public sector organizations, and Securities Services, which offers cross-border support for clients, providing on-the-ground local market expertise, post-trade technologies, customized data solutions, and a wide range of securities services solutions that can be tailored to meet client needs. The Markets segment provides corporate, institutional, and public sector clients around the world with a full range of sales and trading services across equities, foreign exchange, rates, spread products, and commodities. The Banking segment offers Investment Banking and Corporate Lending services. The Wealth segment includes Private Bank, Wealth at Work, and Citigold and provides financial services to a range of client segments through banking, lending, mortgages, investment, custody, and trust product offerings. The USPB segment includes Branded Cards and Retail Services, which have proprietary card portfolios and co-branded card portfolios within Branded Cards, and co-brand and private label relationships within Retail Services. The All Other segment consists of activities not assigned to the reportable operating segments, including certain unallocated costs of global functions, other corporate expenses, and net treasury results. The company was founded in 1812 and is headquartered in New York, NY.

Citigroup Inc

Citigroup is experiencing significant upward momentum, driven by recent regulatory relief, its ongoing strategic transformation, and strong Q3 earnings reported across the financial sector. This rally has propelled the stock to multi-year highs, sparking community debate about its sustainability amidst indicators of overbought conditions and discussions around notable corporate buybacks.

Agios Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in a research engine, multiple novels, and investigational therapies in preclinical development. It focuses on cellular metabolism and classical hematology. The company was founded by Lewis Clayton Cantley, Tak W. Mak, Craig B. Thompson and Shin-Shan Michael Su on August 7, 2007 and is headquartered in Cambridge, MA.

Agios Pharmaceuticals Inc

Agios Pharmaceuticals is a major topic after its drug Aqvesme (mitapivat) secured FDA approval as the only therapy for alpha- and beta-thalassemia, tapping into a significant patient population. While this milestone is driving considerable optimism and discussions of upward potential within the community, some investors are weighing its label, which includes a Risk Evaluation and Mitigation Strategy (REMS), against the stock's recent price movements. This approval marks a key moment, particularly after earlier mixed results from a different clinical program.

Biohaven Ltd. is a global clinical stage biopharmaceutical company, which engages in the discovery, development, and commercialization of therapies for people with neurological and neuropsychiatric diseases. The company was founded on May 2, 2022 and is headquartered in New Haven, CT.

Biohaven Ltd

Biohaven Pharmaceutical Holding Company Ltd

Biohaven is trending as its depression drug candidate failed to meet the primary endpoint in a Phase 2 trial, prompting the company to shift its focus away from psychiatric indications. The community is discussing this latest setback, with many investors now pinning their hopes on the accelerated immunology, obesity, and epilepsy programs, particularly the highly anticipated epilepsy trial, as crucial future catalysts for a potential turnaround.

Sprott Physical Platinum and Palladium Trust - Unit

Sprott Physical Platinum & Palladium

Sprott Physical Platinum & Palladium is gaining significant attention following robust price appreciation, fueled by critical industrial demand for uses like catalytic converters and electronics. Community discussion highlights the metals' under-owned status and supply risks from key producing nations, prompting expectations of a continued breakout as investors seek diversification. Many see potential for Platinum to reclaim its historical premium over gold.

Greenwich LifeSciences, Inc. engages in the development of a breast cancer immunotherapy designed to prevent the recurrence of breast cancer following surgery. The company was founded by Eric Rothe on August 29, 2006 and is headquartered in Stafford, TX.

Greenwich LifeSciences Inc

Greenwich LifeSciences (GLSI) is seeing a surge in attention following preliminary analysis from its FLAMINGO-01 trial, which revealed an estimated 80% reduction in breast cancer recurrence. The community is highly optimistic, citing consistent insider buying by the CEO and an exceptionally high cost-to-borrow rate that has shorts in a precarious position, leading to widespread speculation of an imminent short squeeze. Investors are positioning for potential multi-billion dollar partnerships or a buyout, believing the stock is significantly undervalued given its promising clinical progress in cancer immunotherapy.

iRhythm Technologies, Inc. is a digital healthcare company, which engages in the provision of design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services. It also provides solutions that detect, predict, and prevent disease. The company was founded by Uday N. Kumar in September 2006 and is headquartered in San Francisco, CA.

iRhythm Technologies Inc

iRhythm Technologies is generating significant buzz following a flurry of bullish analyst upgrades and compelling AMALFI study data that validates the superior performance of its Zio service for AFib detection. The community is actively discussing this strong fundamental and institutional interest, which appears to be outweighing recent bearish sentiment, highlighting the company's innovation in the digital cardiac monitoring space. This momentum is further supported by recent positive earnings and strategic operational advancements, positioning IRTC as a key player in healthcare technology.

Dynavax Technologies Corp. is a biopharmaceutical company, which engages in the provision of discovery, development, and commercialization of novel vaccines and immuno-oncology therapeutics. Its product includes HEPLISAV-B, which prevents infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older. The company was founded by Lawrence M. Lichtenstein, Dennis A. Carson, and Eyal Raz on August 29, 1996 and is headquartered in Emeryville, CA.

Dynavax Technologies Corp.

Dynavax is currently a major talking point following the announcement that Sanofi has agreed to acquire the company for $15.50 per share, a deal valued at approximately $2.2 billion to expand Sanofi's adult immunization offerings. While many investors are celebrating the long-awaited exit and the premium offered, a significant portion of the community expresses strong disappointment, arguing the acquisition price notably undervalues Dynavax's Hepatitis B vaccine and promising shingles pipeline.

OpGen, Inc. is a precision medicine company, which engages in the power of molecular diagnostics and informatics to help combat infectious disease. It focuses on the development of molecular information products and services for global healthcare settings. The firm's also offers guidance to clinicians about life threatening infections, improving patient outcomes, and decreasing the spread of infections caused by multidrug-resistant microorganisms. Its products include Unyvero, Acuitas AMR Gene Panel and Acuitas Lighthouse, and the ARES Technology Platform including ARESdb, using NGS technology and AI-powered bioinformatics solutions for antibiotic response prediction. The company was founded on January 22, 2001 and is headquartered in Clarksburg, MD.

Opgen Inc

Opgen (OPGN) is actively discussed for its strategic pivot to an AI-driven fintech platform, CapForce, aimed at Asian markets, backed by significant investment and management changes from AEI Capital. This fundamental business transformation, alongside ongoing efforts to regain Nasdaq listing compliance, is generating strong community enthusiasm, with many anticipating a substantial revaluation once CapForce is fully operational and the stock is relisted.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Orgenesis, Inc. is a biotechnology company, which engages in the development, manufacturing, and provision of technologies, and services in the cell and gene therapy industry. It operates through the following segments: Octomera and Therapies. The Octomera segment refers to the point of care services. The Therapies segment is involved in therapeutic development operations. The company was founded by Sarah Ferber on June 5, 2008 and is headquartered in Germantown, MD.

ORGS
Orgenesis Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest ORGS News

ORGSOrgenesis Inc